News
JUNS
1.140
0.00%
0.000
Vanguard Total Stock Market ETF (VTI) Daily Update—12/09/25
TipRanks · 12h ago
Vanguard Total Stock Market ETF (VTI) Daily Update—12/08/25
TipRanks · 1d ago
Weekly Report: what happened at JUNS last week (1201-1205)?
Weekly Report · 1d ago
Vanguard Total Stock Market ETF (VTI) Daily Update—12/04/25
TipRanks · 5d ago
Jupiter Neurosciences CEO says entering 2026 with ‘momentum, clarity’
TipRanks · 6d ago
VTI ETF Daily Update—12/03/2025
TipRanks · 6d ago
Jupiter Neurosciences to Present at NobleCon21 Emerging Growth Conference
Reuters · 12/02 21:15
VTI ETF Daily Update—12/02/25
TipRanks · 12/02 13:29
VTI ETF Daily Snapshot—12/01/2025
TipRanks · 12/01 11:12
Weekly Report: what happened at JUNS last week (1124-1128)?
Weekly Report · 12/01 09:16
Jupiter Neurosciences Files Prospectus Related To Resale Of Up To 10M Shares Of Our Common Stock By Selling Stockholder
Benzinga · 11/26 22:31
JUPITER NEUROSCIENCES INC - FILES ROSPECTUS RELATED TO RESALE OF UP TO 10 MLN SHARES OF OUR COMMON STOCK BY SELLING STOCKHOLDER
Reuters · 11/26 22:30
VTI ETF Daily Snapshot—11/24/2025
TipRanks · 11/24 12:16
Weekly Report: what happened at JUNS last week (1117-1121)?
Weekly Report · 11/24 09:17
VTI ETF Daily Update — November 21, 2025
TipRanks · 11/21 12:36
Jupiter Neurosciences Issues Amended SEC Filing
Reuters · 11/20 21:06
VTI ETF Daily Report—11/20/2025
TipRanks · 11/20 12:26
VTI ETF Daily Report—11/18/2025
TipRanks · 11/19 13:02
Weekly Report: what happened at JUNS last week (1110-1114)?
Weekly Report · 11/17 09:16
Weekly Report: what happened at JUNS last week (1103-1107)?
Weekly Report · 11/10 09:16
More
Webull provides a variety of real-time JUNS stock news. You can receive the latest news about JUPITER NEUROSCIENCES, INC. through multiple platforms. This information may help you make smarter investment decisions.
About JUNS
Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.